| |
TTD
Drug ID:
DAP000759
| Drug
Information |
| Name | Raltitrexed | | Synonyms | Tomudex, TDX, ZD 1694, Raltitrexed; D 1694; N-(5-(((3,4-Dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl)methylamino)-2-thenoyl)-L-glutamic acid; ZD-1694; AstraZeneca brand of raltitrexed; L-Glutamic acid, N-((5-(((1,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl)methylamino)-2-thienyl)carbonyl)-; 1i00; CPD000469217; SAM001246796; SA-Detection Disk Kit; Bio-0142; 2kce; C21H22N4O6S; Raltitrexed; CHEBI:474007; Raltitrexed (JAN/USAN/INN); 2tsr; CHEBI:41742; CID104758; NSC639186; ZD1694; D16; ZD 1694; SMR000469217; S1192_Selleck; Arkomedika brand of raltitrexed; MLS001424225; (2S)-2-[[5-[methyl-[(2-methyl-4-oxo-1H-quinazolin-6-yl)methyl]amino]thiophene-2-carbonyl]amino]pentanedioic acid; HMS2052I03; ICI D1694; D-1694; Tomudex; KS-5069; D1694; D01064; N-(5-(N-(3,4-Dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino)-2-thenoyl)-L-glutamic acid; DB00293; Tomudex (TN); CHEMBL225071; LS-71840; C068874; AC-19671; ZD-16; 112887-68-0; ZN-D1694; ICI-D1694; NSC-639186; Zeneca brand of raltitrexed; (S)-2-[(1-{5-[Methyl-(2-methyl-4-oxo-3,4-dihydro-quinazolin-6-ylmethyl)-amino]-thiophen-2-yl}-methanoyl)-amino]-pentanedioic acid; ICI-D-1694; AC1L2XFZ; NCI60_013008; C11372 | | Trade Name | Tomudex | | Company | AstraZeneca | | Indication | Colon and rectum cancers | Approved [1] | | Structure |
Click to save drug structure in 3D MOL format
Click to save drug structure in 2D MOL format | | Therapeutic Class | Antineoplastic Agents | | CAS Number | CAS 112887-68-0 | | Formular | C21H22N4O6S | | PubChem Compound ID | CID 104758. | | PubChem Substance ID | SID 13546. | | SuperDrug ATC ID | L01BA03; | | SuperDrug CAS ID | 112887680; | | Target | Thymidylate synthase |  | Inhibitor | [2][3] | | Ref 1 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. To Reference | | Ref 2 | DNA damage and homologous recombination signaling induced by thymidylate deprivation. Biochem Pharmacol. 2008 Oct 15;76(8):987-96. Epub 2008 Aug 19. To Reference | | Ref 3 | Cellular pharmacology of MTA: a correlation of MTA-induced cellular toxicity and in vitro enzyme inhibition with its effect on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells. Semin Oncol. 1999 Apr;26(2 Suppl 6):48-54. To Reference |
Welcome
to sign our Guestbook.
If you
find any error in data or bug in web service, please kindly report it
to Dr.
Zhu.
Dr.
Chen Yuzong
Deputy Director of Center
for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore
All rights reserved.
|
|